

From: Art.4(1)(b) @pfizer.com>
Sent: mardi 16 novembre 2021 13:43
To: Art.4(1)(b) (TRADE); Art.4(1)(b) (TRADE); Art.4(1)(b) (TRADE);
Art.4(1)(b) (TRADE);
Cc: Art.4(1)(b)
Subject: Announcement regarding Medicines Patent Pool (MPP) and Pfizer's Covid-19 Therapeutic Candidate

Dear Art.4(1)(b) Art.4(1)(b) Art.4(1)(b) Art.4(1)(b)

I hope you are all well.

I wanted to let you know that today Pfizer announced that we have entered into a voluntary licensing agreement with the Medicines Patent Pool (MPP) for Pfizer's COVID-19 oral antiviral treatment candidate PF-07321332, ritonavir in low- and middle-income countries.

This agreement will enable qualified generic medicine manufacturers worldwide to produce and supply generic versions of this antiviral, if authorized or approved, to low-income, lower-middle-income and some upper-middle-income countries that make up roughly 53% of the world's population. Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.

As we progress this important candidate and prepare our own manufacturing facilities to ramp up production as quickly as possible, we know that these efforts will only be truly impactful if they can reach those most in need. The MPP has a strong track record with a well-established model, particularly with small molecules, that we believe will offer an efficient way to work within the current innovation ecosystem to help enable broader and faster access for millions.

More information on this announcement can be found via this link:
<https://www.businesswire.com/news/home/20211116005353/en/Pfizer-and-The-Medicines-Patent-Pool-MPP-Sign-Licensing-Agreement-for-COVID-19-Oral-Antiviral-Treatment-Candidate-to-Expand-Access-in-Low--and-Middle-Income-Countries>

As part of our commitment to bring forth scientific breakthroughs to help end this pandemic globally, particularly to the most at-risk, vulnerable populations, we continue to work toward ensuring all people – regardless of where they live or their circumstances – have access. We are pleased to work with MPP to further this commitment to enable greater access to antiviral treatments that may help to reduce the severity of COVID-19 infections, reduce the strain on our healthcare systems and save lives.

We would also be very glad to discuss this news with you further, recognising the importance of the global debate on access to Covid-19 vaccines and therapeutics.

Best wishes,

Art.4(1)(b)

Art.4(1)(b)

Art.4(1)(b)

Boulevard de la Plaine 17, 1050 Brussels, Belgium

+32 Art.4(1)(b) | Art.4(1)(b) [@pfizer.com](mailto:Art.4(1)(b)@pfizer.com)

EU Transparency Register #: 4263301811-33



This e-mail, its contents and any attached file are intended for the named addressee only. This e-mail contains information which may be confidential and which may also be privileged. If you have received this e-mail in error, please notify the sender immediately and then delete it from your system; you may not copy or use it in any way, or disclose, distribute or disseminate this e-mail or its content (or any parts of its content) to anyone. If you are the intended recipient, please only forward this message and/or any attached files to any relevant person on a need to know basis. All messages sent to and from Pfizer may be monitored to ensure compliance with internal policies and to protect our business. Emails are not secure and cannot be guaranteed to be error free as they can be intercepted, amended, lost or destroyed, or contain viruses. Anyone who communicates with us by e-mail is considered to accept these risks.